Evidence map›Paper›PMID 38054350›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Synthetic Biohybrids of Red Blood Cells and Cascaded-Enzymes@ Metal-Organic Frameworks for Hyperuricemia Treatment.

Zeyu Li, Liecong Xue, Junxian Yang, Stefan Wuttke, Peiying He, Chuanyi Lei, Haowei Yang, Liang Zhou, Jiangfan Cao, Anna Sinelshchikova and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Biomedical Applications of Metal-Organic Frameworks Revisited.Industrial & engineering chemistry research · 2025
    Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Zeyu LiMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Liecong XueMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Junxian YangMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510000, P. R. China.
Stefan WuttkeBCMaterials, Basque Center for Materials, UPV/EHU Science Park, Leioa, 48940, Spain.
Peiying HeMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Chuanyi LeiMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Haowei YangChina National Tobacco Corporation, No.55 South Yuetan Boulevard Xicheng District, Beijing, 100045, P. R. China.
Liang ZhouMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Jiangfan CaoMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Anna SinelshchikovaBCMaterials, Basque Center for Materials, UPV/EHU Science Park, Leioa, 48940, Spain.
Guansheng ZhengMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
Jimin GuoCollege of Materials Sciences and Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.
Jiangguo LinMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510000, P. R. China.
Qi LeiThe Second Affiliated Hospital, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy and Clinical Immunology, Guangzhou Medical University, Guangzhou, 510260, P.R. China.
C Jeffrey BrinkerCenter for Micro-Engineered Materials and the Department of Chemical and Biological Engineering, The University of New Mexico, Albuquerque, NM, 87131, USA.
Kaisheng LiuGuangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, P. R. China.
Wei ZhuMOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.ORCID 0000-0003-3240-6905
South China University of Technology · CNGuangdong Academy of Medical Sciences · CNBasque Center for Materials, Applications and Nanostructures · ESBeijing University of Chemical Technology · CNChina Tobacco · CNIkerbasque · ESJinan University · CNSecond Affiliated Hospital of Guangzhou Medical University · CNUniversity of New Mexico · US

Funding

Fundamental Research Funds for the Central UniversitiesGuangdong Provincial Pearl River Talents Program 2019QN01Y314National Natural Science Foundation of China 21972047National Natural Science Foundation of China 22372061Natural Science Foundation of Guangdong Province 2021A1515010724Natural Science Foundation of Guangdong Province 2021A1515220051Natural Science Foundation of Guangdong Province 2022A0505050008Program for Guangdong Introducing Innovative and Entrepreneurial Teams 2019ZT08Y318Science and Technology Project of Guangzhou 202102020259Science and Technology Project of Guangzhou 202102020352
6 · The paper itself

Abstract

Hyperuricemia, caused by an imbalance between the rates of production and excretion of uric acid (UA), may greatly increase the mortality rates in patients with cardiovascular and cerebrovascular diseases. Herein, for fast-acting and long-lasting hyperuricemia treatment, armored red blood cell (RBC) biohybrids, integrated RBCs with proximal, cascaded-enzymes of urate oxidase (UOX) and catalase (CAT) encapsulated within ZIF-8 framework-based nanoparticles, have been fabricated based on a super-assembly approach. Each component is crucial for hyperuricemia treatment: 1) RBCs significantly increase the circulation time of nanoparticles; 2) ZIF-8 nanoparticles-based superstructure greatly enhances RBCs resistance against external stressors while preserving native RBC properties (such as oxygen carrying capability); 3) the ZIF-8 scaffold protects the encapsulated enzymes from enzymatic degradation; 4) no physical barrier exists for urate diffusion, and thus allow fast degradation of UA in blood and neutralizes the toxic by-product H

Indexed as

HyperuricemiaMetal-Organic FrameworksAnimalsDisease Models, AnimalErythrocytesHumansMiceUric AcidMetal-Organic FrameworksUric Acidbiohybrid materialsenzymehyperuricemiaMetal-organic Frameworksred blood cells

Identifiers

PMID38054350
PMCPMC10837374
OpenAlexW4389391669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.